...
首页> 外文期刊>Clinical Chemistry >The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
【24h】

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

机译:MIQE指南:发布定量实时PCR实验的最低信息

获取原文
获取原文并翻译 | 示例

摘要

Currently, a lack of consensus exists on how best to perform and interpret quantitative real-time PCR (qPCR) experiments. The problem is exacerbated by a lack of sufficient experimental detail in many publications, which impedes a reader's ability to evaluate critically the quality of the results presented or to repeat the experiments. The Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines target the reliability of results to help ensure the integrity of the scientific literature, promote consistency between laboratories, and increase experimental transparency. MIQE is a set of guidelines that describe the minimum information necessary for evaluating qPCR experiments. Included is a checklist to accompany the initial submission of a manuscript to the publisher. By providing all relevant experimental conditions and assay characteristics, reviewers can assess the validity of the protocols used. Full disclosure of all reagents, sequences, and analysis methods is necessary to enable other investigators to reproduce results. MIQE details should be published either in abbreviated form or as an online supplement. Following these guidelines will encourage better experimental practice, allowing more reliable and unequivocal interpretation of qPCR results.
机译:当前,在如何最好地执行和解释定量实时PCR(qPCR)实验方面尚无共识。由于许多出版物缺乏足够的实验细节,使问题更加严重,这阻碍了读者对所给出结果的质量进行严格评估或重复实验的能力。 《发布定量实时PCR实验(MIQE)的最低信息》指南的目标是确保结果的可靠性,以帮助确保科学文献的完整性,促进实验室之间的一致性并提高实验的透明度。 MIQE是一组准则,描述了评估qPCR实验所需的最少信息。随附一份清单,以初次向出版商提交手稿。通过提供所有相关的实验条件和测定特征,审阅者可以评估所用方案的有效性。为了使其他研究人员能够再现结果,必须全面披露所有试剂,序列和分析方法。 MIQE详细信息应以缩写形式或在线补充形式发布。遵循这些准则将鼓励更好的实验方法,从而对qPCR结果进行更可靠和明确的解释。

著录项

  • 来源
    《Clinical Chemistry》 |2009年第4期|p.611-622|共12页
  • 作者单位

    Stephen A. Bustin,1* Vladimir Benes,2 Jeremy A. Garson,3,4 Jan Hellemans,5 Jim Huggett,6 Mikael Kubista,7,8 Reinhold Mueller,9 Tania Nolan,10 Michael W. Pfaffl,11 Gregory L. Shipley,12 Jo Vandesompele,5 and Carl T. Wittwer13,141 Centre for Academic Surgery, Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK, 2 Genomics Core Facility, EMBL Heidelberg, Heidelberg, Germany, 3 Centre for Virology, Department of Infection, University College London, London, UK, 4 Department of Virology, UCL Hospitals NHS Foundation Trust, London, UK, 5 Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium, 6 Centre for Infectious Diseases, University College London, London, UK, 7 TATAA Biocenter, Go teborg, Sweden, 8 Institute of Biotechnology AS CR, Prague, Czech Republic, 9 Sequenom, San Diego, California, USA, 10 Sigma-Aldrich, Haverhill, UK, 11 Physiology Weihenstephan, Technical University Munich, Freising, Germany, 12 Quantitative Genomics Core Laboratory, Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas, USA, 13 Department of Pathology, University of Utah, Salt Lake City, Utah, USA, 14 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA.* Address correspondence to this author at: 3rd Floor Alexandra Wing, The Royal London Hospital, London E1 1BB, UK. Fax 44-(0)20-7377 7283, e-mail s.a.bustin@qmul.ac.uk.Received October 20, 2008, accepted January 27, 2009.Previously published online at DOI: 10.1373/clinchem.2008.112797Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, (b) drafting or revising the article for intellectual content, and (c) final approval of the published article.Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:Employmentor Leadership: J. Hellemans, Biogazelle, J. Vandesompele, Biogazelle, C.T. Wittwer, Idaho Technology.Consultant or Advisory Role: R. Mueller, DermTech International.Stock Ownership: R. Mueller, Sequenom, C.T. Wittwer, Idaho Technology.Honoraria: None declared.Research Funding: S.A. Bustin, Bowel and Cancer Research, registered charity number 1119105, J. Hellemans, Fund for Scientific Research Flanders, M. Kubista, grant agency of the Academy of Sciences, Czech Republic (grants IAA500520809 and AV0250520701), C.T. Wittwer, ARUP Institute for Clinical and Experimental Pathology and Idaho Technology.Expert Testimony: None declared.Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号